ResearcherPeking University Cancer HospitalActive in the last 2 years

Professor Lin Shen

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 6 November 2026

Known by name at one institution; no external author ID yet. Sources: ClinicalTrials.gov.

Their work

Papers: 0
Trials: 3 (principal investigator on 3)
Grants: 0
Labs led: 0
Collaborators: 1

Papers, trials and grants by year

2018: 1 trial · 2019: none · 2020: 1 trial · 2021: none · 2022: none · 2023: none · 2024: 1 trial

Trials 3

NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor Principal investigator NCT06134960 ↗
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection Principal investigator NCT04581473 ↗
Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic Cancer Principal investigator NCT03636308 ↗

Closest collaborators

The 1 strongest of 1 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Professor Xianjun Yu · 1 shared trial, 2020 · strength 0.36
- Trial Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection NCT04581473 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.